Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer

Sur, Ranjan; Donde, Bernard; Falkson, Conrad; Ahmed, Sheikh N.; Levin, V. N.; Nag, Subir; Wong, Raimond; Jones, Glenn

doi:10.1016/j.brachy.2004.09.004

Cited by 58 publications

(35 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is suggested by the short time frame between the study intervention and the occurrence of intervention-related major complications (a median of 6 days). Previous studies on brachytherapy that used a comparable radiation dose as single modality treatment reported the occurrence of major complications not before a follow-up time of 90 days or more, 18,19 which precludes that these effects are attributable to the brachytherapy. In the above-mentioned studies from Asia investigating combination therapy (with SEMSs), major complications also were seen 8 to 12 weeks after radiotherapy had been administered.…”

Section: Discussionmentioning

confidence: 96%

Combination of biodegradable stent placement and single-dose brachytherapy is associated with an unacceptably high complication rate in the treatment of dysphagia from esophageal cancer

Hirdes

Hooft

Wijrdeman

et al. 2012

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Combination of biodegradable stent placement and single-dose brachytherapy is associated with an unacceptably high complication rate in the treatment of dysphagia from esophageal cancer

Hirdes

Hooft

Wijrdeman

et al. 2012

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

“…Brachytherapy is the strategy with the highest probability of cost-effectiveness of all values yielding a positive net health benefit the advent of endoluminal therapies have permitted improvement in survival and delivery of effective methods of palliation using less invasive techniques and at lower costs. Different modalities such as Nd:YAG laser, SES and brachytherapy, are available, and numerous studies have validated their efficacy [4,[6][7][8][17][18][19][20][21][22][23][24][25]. Although palliation can be achieved with any one of the existent techniques, a systematic, cost-effective approach to manage this condition was lacking.…”

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness of Palliation of Unresectable Esophageal Cancer

Silveira

Artifon

2008

Dig Dis Sci

View full text Add to dashboard Cite

show abstract

“…A pilot RCT compared ILBT with ILBT + EBRT 14 with a view to identifying any survival benefit with the addition of EBRT. The patients were younger than in other studies with a mean age of 53.4 years.…”

Section: Discussionmentioning

confidence: 99%

Intraluminal high-dose-rate brachytherapy for palliation of dysphagia in cancer of the esophagus: initial experience at a single UK center

Bhatt

Tirmazy

Sothi

2012

Diseases of the Esophagus

View full text Add to dashboard Cite

Esophageal cancer tends to present with advanced disease, and the majority of patients are suitable only for palliative treatment at diagnosis. Dysphagia is the most common presenting symptom and significantly undermines quality of life. High-dose-rate intraluminal brachytherapy (ILBT) has been an option for the palliation of dysphagia for many years and has been used at our center since 2006. Experience was presented in terms of improvement of dysphagia and survival. Patients were identified from the local radiotherapy database. Original treatment sheets and clinical notes were reviewed retrospectively to obtain treatment details, pretreatment and post-treatment dysphagia scores, and survival information. Between January 2006 and January 2010, 21 patients of median age 77 years with a mean pretreatment dysphagia score of 2.5 underwent ILBT for esophageal cancer. All received 12 Gy in a single fraction. Thirteen (62%) had adenocarcinoma and eight (38%) squamous cell carcinoma. Four (19%) tumors were in the mid-esophagus and 17 (81%) in the lower esophagus. Eight had extension of tumor into the gastroesophageal junction. Seven patients (33%) received chemotherapy as first-line treatment prior to brachytherapy. Nineteen patients had clear documentation of dysphagia scores both pretreatment and post-treatment, and the improvement overall was significant (P= 0.04). Ten patients (53%) had an improvement in dysphagia score. Five of these (50%) went on to require further endoscopic intervention due to disease progression. Median duration of response was 4 months. Of the nonresponders, six (67%) went on to require further endoscopic intervention. No patients experienced documented toxicity aside from a short-lived acute esophagitis. Median survival from date of diagnosis was 12 months and from treatment date was 5 months (1-32 months). In our series of elderly patients with significant dysphagia, ILBT was a well-tolerated and effective treatment. It should be considered as a palliative option in esophageal cancer.

show abstract

Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer

Cited by 58 publications

References 12 publications

Combination of biodegradable stent placement and single-dose brachytherapy is associated with an unacceptably high complication rate in the treatment of dysphagia from esophageal cancer

Combination of biodegradable stent placement and single-dose brachytherapy is associated with an unacceptably high complication rate in the treatment of dysphagia from esophageal cancer

Cost-Effectiveness of Palliation of Unresectable Esophageal Cancer

Intraluminal high-dose-rate brachytherapy for palliation of dysphagia in cancer of the esophagus: initial experience at a single UK center

Contact Info

Product

Resources

About